Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)

El Institut Germans Trias (IGTP) es un centro CERCA, centro público de investigación catalán que tiene como objetivo contribuir a la mejora de la salud de las personas a través del conocimiento científico y de su transferencia. Acreditado como centro de excelencia por el Instituto de Salud Carlos III, y paraguas de la actividad investigadora del Hospital Germans Trias (HUGTP). El IGTP está ubicado en el Campus Can Ruti de Badalona, donde está fuertemente conectado con el resto de instituciones que hacen investigación: Institut Català d’Oncologia (ICO), Institut de Recerca de la Sida IrsiCaixa, Universitat Autònoma de Barcelona (UAB), Institut Guttmann, Institut de Recerca contra la Leucèmia Josep Carreras (IJC), Fundació Lluita contra la Sida (FLS), Institut de Medicina Predictiva i Personalitzada del Càncer (IMPPC), Banc de Sang i Teixits (BST) y el Centre d’Estudis Epidemiològics sobre les Infeccions de Transmissió Sexual i Sida de Catalunya (CEEISCAT).

La actividad de investigación del IGTP se distribuye en 8 áreas, que suponen medio millar de publicaciones científicas anuales en prestigiosas revistas científicas. Estas áreas son: Ciencias del comportamiento y abuso de sustancias; Inmunología y inflamación; Enfermedades del corazón, vasculares y respiratorias; Enfermedades infecciosas; Enfermedades endocrino-metabólicas, del hueso y renales; Hígado y aparato digestivo; Cáncer y Neurociencias. Además, el Institut dispone de múltiples plataformas tecnológicas y unidades que dan un apoyo imprescindible a los investigadores.

Estadísticas de uso Los más consultados
Últimas adquisiciones:
2019-05-30
12:35
10 p, 290.8 KB Alectinib versus crizotinib in untreated ALK-positive non–small-cell lung cancer / Peters, S. (Lausanne University Hospital) ; Camidge, D.R. (University of Colorado) ; Shaw, A.T. (Massachusetts General Hospital) ; Gadgeel, S. (University of Michigan) ; Ahn, J.S. (Samsung Medical Center. Sungkyunkwan University School of Medicine) ; Kim, D.W. (Seoul National University Hospital) ; Ou, S.H.I. (School of Medicine) ; Pérol, M. (Department of Medical Oncology. Léon Bérard Cancer Center) ; Dziadziuszko, R. (Department of Oncology and Radiotherapy. Medical University of Gdansk) ; Rosell, R. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Zeaiter, A. (F. Hoffmann–La Roche) ; Mitry, E. (F. Hoffmann–La Roche) ; Golding, S. (F. Hoffmann–La Roche) ; Balas, B. (F. Hoffmann–La Roche) ; Noe, J. (F. Hoffmann–La Roche) ; Morcos, P.N. (Roche Innovation Center) ; Mok, T. (State Key Laboratory of South China. Chinese University of Hong Kong)
BACKGROUND: Alectinib, a highly selective inhibitor of anaplastic lymphoma kinase (ALK), has shown systemic and central nervous system (CNS) efficacy in the treatment of ALK-positive non–small-cell lung cancer (NSCLC). [...]
2017 - 10.1056/NEJMoa1704795
New England Journal of Medicine, Vol. 377 Núm. 9 (31 2017) , p. 829-838  
2019-05-28
09:44
270 p, 2.5 MB Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus / Hemmingsen, B. (Herlev University Hospital. Department of Internal Medicine) ; Gimenez-Perez, G. (Hospital General de Granollers) ; Mauricio, D. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Roqué i Figuls, M. (Institut d'Investigació Biomèdica Sant Pau) ; Metzendorf, M.I. (Institute of General Practice. Medical Faculty of the Heinrich-Heine-University Düsseldorf) ; Richter, B. (Institute of General Practice. Medical Faculty of the Heinrich-Heine-University Düsseldorf)
Background: The projected rise in the incidence of type 2 diabetes mellitus (T2DM) could develop into a substantial health problem worldwide. Whether diet, physical activity or both can prevent or delay T2DM and its associated complications in at-risk people is unknown. [...]
2017 - 10.1002/14651858.CD003054.pub4
Cochrane Database of Systematic Reviews, Vol. 2017 Núm. 12 (april 2017) , p. CD003054  
2019-05-06
04:08
6 p, 1.9 MB Heart–lung–muscle anti-SAE syndrome : an atypical severe combination / Zamora Serrallonga, Elisabet (Universitat Autònoma de Barcelona. Departament de Medicina) ; Seder Colomina, Elena (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol. Servei de Cardiologia) ; Holgado Pérez, Susana (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol. Servei de Reumatologia) ; Quirant Sanchez, Bibiana (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol. Servei d'Immunologia) ; Mate Sanz, José Luis (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol. Servei de Patologia) ; Martínez Cáceres, Eva M. (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ; Casafont Solé, Ivette (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol. Servei de Reumatologia) ; Bayés Genís, Antoni (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol. Servei de Cardiologia)
A 78-year-old man with 3 months of progressive dyspnea, dysphony, dysgeusia, and proximal muscle weakness was diagnosed of probably idiopathic inflammatory myopathy with nonspecific interstitial pneumonia. [...]
2019 - 10.3390/jcm8010020
Journal of clinical medicine, Vol. 8, issue 1 (Jan. 2019) , art. 20  
2019-04-02
16:28
10 p, 1.6 MB International sentinel site surveillance of patients with transfusional hemosiderosis treated with deferasirox in actual practice setting / El-Beshlawy, Amal (Cairo University) ; Inusa, Baba (Evelina Children's Hospital) ; Beneitez Pastor, David (Hospital Universitari Vall d'Hebron. Departament d'Hematologia) ; Xicoy, Blanca (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Duran Nieto, Maria Soledad (Hospital Materno Infantil de Jaén) ; Bruederle, Andreas (Novartis Pharma AG) ; Azmon, Amin (Novartis Pharma AG, Switzerland) ; Gilotti, Geralyn (Novartis Pharmaceuticals Corporation, USA) ; Elalfy, Mohsen (Ain Shams University, Cairo) ; Universitat Autònoma de Barcelona
Objective:The study evaluates the long-term deferasirox treatment of adult and pediatricpatients with chronic transfusional iron overload in clinical practice. Methods:In this non-interventional study, patients were observed for up to 3 years frominitiation of deferasirox treatment both prospectively and retrospectively for up to 1 yearprior to enrollment. [...]
2019 - 10.1080/16078454.2018.155875
Hematology, 2019  
2019-04-01
15:20
13 p, 2.7 MB Minimal residual disease level predicts outcome in adults with Ph-negative Bprecursor acute lymphoblastic leukemia / Gökbuget, Nicola (Department of Medicine II, Department of Hematology/Oncology, University Hospital, Frankfurt, Germany) ; Dombret, Hervé (Hôpital Saint-Louis, Université Paris Diderot) ; Giebel, Sebastian (Maria Sklodowska Curie Memorial Cancer Center, Gliwice) ; Bruggemann, Monika (Department of Hematology and Oncology, University Hospital Schleswig-Holstein) ; Doubek, Michael (Department of Internal Medicine, Hematology and Oncology,University Hospital, Brno, Czech Republic) ; Foà, Robin (Sapienza University of Rome) ; Hoelzer, Dieter (Department of Medicine II, Department of Hematology/Oncology, University Hospital, Frankfurt, Germany) ; Kim, Christopher (Amgen Inc, Thousand Oaks, CA, USA) ; Martinelli, Giovanni (Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS) ; Parovichnikova, Elena (National Research Center for Hematology, Moscow) ; Rambaldi, Alessandro (Dipartimento di Oncologia ed Ematologia, Università degli Studi di Milano and Ospedale Papa Giovanni XXIII) ; Ribera, Josep Maria (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Schoonen, Marieke (Amgen Ltd, London) ; Stieglmaier, Julia M. (Amgen GmBH, Munich) ; Zugmaier, Gerhard (Amgen GmBH, Munich) ; Bassan, Renato (Ospedale dell’Angelo, Mestre-Venezia) ; Universitat Autònoma de Barcelona
Objectives: Detectable minimal residual disease (MRD) after therapy for acute lymphoblastic leukemia (ALL) is the strongest predictor of hematologic relapse. This study evaluated outcomes of patients with B-cell precursor ALL with MRD of ≥10−4. [...]
2019 - 10.1080/16078454.2019.1567654
Hematology, Vol. 24 Núm. 1 (2019) , p. 337-348  
2019-01-16
11:28
18 p, 288.5 KB Translational research opportunities regarding homologous recombination in ovarian cancer / Romeo Marín, Margarita (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Pardo, J.C. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Martínez Cardús, Anna (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Martínez Balibrea, Eva (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Quiroga, Vanesa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Martínez Román, Sergio (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Solé, Francesc (Institut Germants Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Margelí, Mireia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Mesía, Ricard (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Universitat Autònoma de Barcelona
Homologous recombination (HR) is a DNA repair pathway that is deficient in 50% of high-grade serous ovarian carcinomas (HGSOC). Deficient HR (DHR) constitutes a therapeutic opportunity for these patients, thanks to poly (ADP-ribose) polymerases (PARP) inhibitors (PARPi; olaparib, niraparib, and rucaparib are already commercialized). [...]
2018 - 10.3390/ijms19103249
International Journal of Molecular Sciences, Vol. 19 Núm. 10 (19 2018) , p. 3249  
2018-12-24
03:55
10 p, 1.9 MB Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer / Codony Servat, Jordi (Institut Germans Trias i Pujol. Institut Català d'Oncologia) ; Cuatrecasas Freixas, Miriam ; Asensio, Elena (Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)) ; Montironi, Carla (Hospital Clínic) ; Martínez Cardús, Anna (Institut Germans Trias i Pujol. Institut Català d'Oncologia) ; Marín Aguilera, Mercedes (Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)) ; Horndler, Carlos (Hospital Miguel Servet) ; Martínez Balibrea, Eva (Institut Germans Trias i Pujol. Institut Català d'Oncologia) ; Rubini, Michele (Department of Experimental and Diagnostic Medicine, University of Ferrara) ; Jares, Pedro (Hospital Clínic) ; Reig, Oscar (Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)) ; Victoria, Iván (Medical Oncology Department, Hospital Clínic, Translational Genomics and Targeted Therapeutics in Solid Tumors Group, IDIBAPS, Universitat de Barcelona) ; Gaba, Lydia (Medical Oncology Department, Hospital Clínic, Translational Genomics and Targeted Therapeutics in Solid Tumors Group, IDIBAPS, Universitat de Barcelona) ; Martín Richard, Marta (Institut d'Investigació Biomèdica Sant Pau) ; Alonso, Vicente (Hospital Miguel Servet) ; Escudero, Pilar (Hospital Clínico Universitatio Lozano Blesa) ; Fernández-Martos, Carlos (Instituto Valenciano de Oncología) ; Feliu, Jaime (Hospital La Paz, CIBERONC) ; Méndez, Jose Carlos (Centro Oncológico de Galicia) ; Méndez, Miguel (Hospital de Móstoles) ; Gallego, Javier (Hospital de Elche) ; Salud, Antonieta (Hospital Arnau de Vilanova) ; Rojo, Federico (Pathology Department, Fundación Jiménez Diaz University) ; Castells, Antoni (Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)) ; Prat, Aleix (Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)) ; Rosell, Rafael (Institut Germans Trias i Pujol. Institut Català d'Oncologia) ; García-Albéniz, Xabier (Harvard T.H. Chan School of Public Health) ; Camps, Jordi (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, Fisiologia i Immunologia) ; Maurel, Joan (Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS))
Although chemotherapy is the cornerstone treatment for patients with metastatic colorectal cancer (mCRC), acquired chemoresistance is common and constitutes the main reason for treatment failure. Monoclonal antibodies against insulin-like growth factor-1 receptor (IGF-1R) have been tested in pre-treated mCRC patients, but results have been largely deceiving. [...]
2017 - 10.1038/bjc.2017.279
British Journal of Cancer, Vol. 117 (november 2017) , p. 1777-1786  
2018-11-01
22:41
From exome analysis in idiopathic azoospermia to the identification of a high-risk subgroup for occult Fanconi anemia / Krausz, Csilla (Institut d'Investigació Biomèdica Sant Pau) ; Riera-Escamilla, Antoni (Institut d'Investigació Biomèdica Sant Pau) ; Chianese, Chiara (Institut d'Investigació Biomèdica Sant Pau) ; Moreno-Mendoza, Daniel (Institut d'Investigació Biomèdica Sant Pau) ; Ars Criach, Elisabet (Institut d'Investigació Biomèdica Sant Pau) ; Rajmil, Osvaldo (Institut d'Investigació Biomèdica Sant Pau) ; Pujol i Calvet, M. Roser (Universitat Autònoma de Barcelona. Departament de Genètica i de Microbiologia) ; Bogliolo, Massimo (Universitat Autònoma de Barcelona. Departament de Genètica i de Microbiologia) ; Blanco, Ignacio (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Rodríguez, Inés (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Badell Serra, Isabel (Universitat Autònoma de Barcelona. Departament de Pediatria, Obstetrícia i Ginecologia i de Medicina Preventiva i Salut Pública) ; Ruiz-Castañé, Eduard (Institut d'Investigació Biomèdica Sant Pau) ; Surrallés i Calonge, Jordi (Universitat Autònoma de Barcelona. Departament de Genètica i de Microbiologia)
Purpose: in about 10% of patients affected by Fanconi anemia (FA) the diagnosis is delayed until adulthood, and the presenting symptom in these "occult" FA cases is often a solid cancer and cancer treatment-related toxicity. [...]
2019 - 10.1038/s41436-018-0037-1
Genetics in Medicine, Vol. 21, issue 1 (Jan. 2019) , p. 189-194  
2018-10-26
18:13
9 p, 1.2 MB Antibodies against peripheral nerve antigens in chronic inflammatory demyelinating polyradiculoneuropathy / Querol, Luis (Institut d'Investigació Biomèdica Sant Pau) ; Siles, Ana M (Institut d'Investigació Biomèdica Sant Pau) ; Alba-Rovira, Roser (Institut d'Investigació Biomèdica Sant Pau) ; Jáuregui, Agustín (Fundación Favaloro, Buenos, Aires, Argentina) ; Devaux, Jérôme (Aix-Marseille Université) ; Faivre-Sarrailh, Catherine (Aix-Marseille Université) ; Araque,Josefa (Institut d'Investigació Biomèdica Sant Pau) ; Rojas Garcia,Ricard (Institut d'Investigació Biomèdica Sant Pau) ; Diaz Manera, Jordi (Institut d'Investigació Biomèdica Sant Pau) ; Cortés Vicente, Elena (Institut d'Investigació Biomèdica Sant Pau) ; Nogales Gadea,Gisela (Institut Germans Trias i Pujol) ; Navas Madroñal, Miquel (Institut d'Investigació Biomèdica Sant Pau) ; Gallardo Vigo, Eduard (Institut d'Investigació Biomèdica Sant Pau) ; Illa, Isabel (Institut d'Investigació Biomèdica Sant Pau)
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a heterogeneous disease in which diverse autoantibodies have been described but systematic screening has never been performed. Detection of CIDP-specific antibodies may be clinically useful. [...]
2017 - 10.1038/s41598-017-14853-4
Sientific reports, Vol. 7 (october 2017) , p. 1-9  
2018-10-26
18:09
12 p, 5.0 MB Characterization of an anti-fetal AChR monoclonal antibody isolated from a myasthenia gravis patient / Saxena, Abhishek (Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University) ; Stevens, Jo (Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University) ; Cetin,Hakan (Nuffield Department of Clinical Neurosciences, John Radcliffe University Hospital, Oxford) ; Koneczny, Inga (Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University) ; Webster, Richard (Nuffield Department of Clinical Neurosciences, John Radcliffe University Hospital, Oxford) ; Lazaridis, Konstantinos (Hellenic Pasteur Institute) ; Tzartos, Socrates (Hellenic Pasteur Institute) ; Vrolix, Kathleen (Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University) ; Nogales-Gadea, Gisela (Institut Germans Trias i Pujol. Recerca Neuromuscular i Neuropediàtrica) ; Machiels, Barbie (Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University) ; Molenaar, Peter C. (Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University) ; Damoiseaux, Jan (Central Diagnostic Laboratory, Maastricht University Medical Center) ; De Baets, Marc H. (Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University) ; Simon-Keller, Katja (Institute of Pathology, University Medical Centre Mannheim, University of Heidelberg) ; Marx, Alexander (Institute of Pathology, University Medical Centre Mannheim, University of Heidelberg) ; Vincent, Angela (Nuffield Department of Clinical Neurosciences, John Radcliffe University Hospital, Oxford) ; Mario Losen (Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University) ; Pilar Martinez-Martinez (Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University) ;
We report here the sequence and functional characterization of a recombinantly expressed.
autoantibody (mAb 131) previously isolated from a myasthenia gravis patient by immortalization of thymic B cells using Epstein-Barr virus and TLR9 activation. The antibody is characterized by a high degree of somatic mutations as well as a 6 amino acid insertion within the VHCDR2. [...]

2017 - 10.1038/s41598-017-14350-8
Sientific reports, Vol. 7 (october 2017) , p. 1-12